Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

Core Viewpoint - Tiziana Life Sciences is advancing its intranasal foralumab, a fully human anti-CD3 monoclonal antibody, showing promising results in treating traumatic spinal cord injury (SCI) through modulation of microglial inflammation [1][4][5]. Group 1: Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies, particularly intranasal routes for immunotherapy [8]. - The lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, demonstrating a favorable safety profile and clinical response in prior studies [8]. Group 2: Research Findings - Preclinical studies indicate that treatment with nasal anti-CD3 significantly improves motor functions in models of spinal cord injury by dampening microglial activation [2][5]. - Approximately 300,000 individuals in the U.S. are living with spinal cord injuries, with over 17,000 new cases reported annually, highlighting the urgent need for effective treatments [3]. Group 3: Scientific Insights - The inflammatory response mediated by microglia is crucial in the pathogenesis of spinal cord injuries, and nasal anti-CD3 plays a pivotal role in modulating this inflammation [2][4]. - Foralumab stimulates T regulatory cells when administered intranasally, which may lead to reduced inflammation and improved outcomes in neuroinflammatory conditions [6][7].